State insurance mandates and racial and ethnic inequities in assisted reproductive technology utilization.


Journal

Fertility and sterility
ISSN: 1556-5653
Titre abrégé: Fertil Steril
Pays: United States
ID NLM: 0372772

Informations de publication

Date de publication:
01 2024
Historique:
received: 16 03 2023
revised: 20 09 2023
accepted: 20 09 2023
medline: 8 1 2024
pubmed: 30 9 2023
entrez: 29 9 2023
Statut: ppublish

Résumé

To examine whether the (1) scope of state-mandated insurance coverage for assisted reproductive technology (ART) and (2) proportion of the population eligible for this coverage are associated with reductions in racial/ethnic inequities in ART utilization. National cross-sectional, ecologic study. We employed estimates from the US Census Bureau of all women 20-44 years of age living in the US in 2018. Data on the number of women who initiated an ART cycle during that year that were reported to the US Centers for Disease Control and Prevention were obtained from the National ART Surveillance System. State mandates were classified according to the scope of required coverage for fertility services: Comprehensive, Limited, and No Mandate. Race and ethnic-specific ART utilization rates, defined as the number of women undergoing ≥1 ART cycles per 10,000 women, were the primary outcomes. As state mandates do not apply to all insurance plans, Comprehensive Mandate utilization rates were recalculated using denominators corrected for the estimated proportions of populations eligible for coverage. Across all mandate categories, Non-Hispanic (NH) Asian and NH White populations had the highest ART utilization rates, whereas the lowest rates were among Hispanic, NH Black, and NH Other/Multiple Races populations. Compared with the NH Asian reference group, the NH Black population had smaller inequities in the Comprehensive Mandate group than the No Mandate group (rate ratio [RR 0.33 [0.28-0.38] vs. RR 0.23 [0.22-0.24]). Using the Comprehensive Mandate group for each race/ethnicity as the reference, the NH Black and NH Other/Multiple Races populations showed the largest relative differences in utilization between the No Mandate and Comprehensive Mandate groups (RR 0.39 [0.37-0.41] and 0.33 [0.28-0.38], respectively). Within the Comprehensive Mandate group, the disparities in the Hispanic and NH Black populations moved toward the null after correcting for state-mandated insurance eligibility. Racial/ethnic inequities in ART utilization were reduced in states with comprehensive infertility coverage mandates. Inequities were further attenuated after correcting for mandate eligibility. Mandates alone, however, were not sufficient to eliminate disparities. These findings can inform future strategies aimed at improving ART access under a social justice framework.

Identifiants

pubmed: 37775023
pii: S0015-0282(23)01881-2
doi: 10.1016/j.fertnstert.2023.09.015
pmc: PMC10951934
mid: NIHMS1968323
pii:
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't Research Support, N.I.H., Extramural

Langues

eng

Sous-ensembles de citation

IM

Pagination

54-62

Subventions

Organisme : Intramural CDC HHS
ID : CC999999
Pays : United States
Organisme : NCATS NIH HHS
ID : UL1 TR002541
Pays : United States

Commentaires et corrections

Type : CommentIn

Informations de copyright

Copyright © 2023 American Society for Reproductive Medicine. Published by Elsevier Inc. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of interests A.K. has nothing to disclose. C.D. has nothing to disclose. D.K. has nothing to disclose. M.H. has nothing to disclose. K.K. has nothing to disclose. A.Y. has nothing to disclose. E.A. has nothing to disclose. A.P. has nothing to disclose.

Références

Int J Stat Med Res. 2022 Jan 28;11:1-11
pubmed: 35368775
Fertil Steril. 2011 Mar 1;95(3):964-9
pubmed: 20688327
J Law Med Ethics. 2009 Fall;37 Suppl 2:86-100
pubmed: 19754654
Fertil Steril. 2006 Apr;85(4):858-65
pubmed: 16580365
J Immigr Minor Health. 2014 Oct;16(5):1001-6
pubmed: 23475348
F S Rep. 2022 Apr 04;3(2 Suppl):46-54
pubmed: 35937452
Fertil Steril. 2010 Feb;93(2):382-90
pubmed: 19081561
Fertil Steril. 2006 Apr;85(4):876-81
pubmed: 16580368
F S Rep. 2022 Aug 12;3(4):305-310
pubmed: 36568920
J Womens Health (Larchmt). 2017 Jun;26(6):605-608
pubmed: 28586255
Race Soc Probl. 2012 Dec 1;4(3-4):158-170
pubmed: 23565127
Fertil Steril. 2013 Jun;99(7):2025-30
pubmed: 23454007
J Am Med Inform Assoc. 2019 Aug 1;26(8-9):722-729
pubmed: 31329882
J Aging Health. 2006 Oct;18(5):707-21
pubmed: 16980636
J Health Econ. 2007 May 1;26(3):431-46
pubmed: 17129624
N Engl J Med. 2002 Aug 29;347(9):661-6
pubmed: 12200554
Ethn Dis. 2004 Autumn;14(4):580-3
pubmed: 15724779
Am J Obstet Gynecol. 2022 Jul;227(1):64.e1-64.e8
pubmed: 35283088
Fertil Steril. 2021 Jan;115(1):29-42
pubmed: 33342534
Natl Health Stat Report. 2014 Jan 22;(73):1-21
pubmed: 24467919
N Engl J Med. 2021 Feb 25;384(8):768-773
pubmed: 33326717
Fertil Steril. 2012 Aug;98(2):406-9
pubmed: 22698638
Demography. 2012 Feb;49(1):125-49
pubmed: 22167581
Popul Res Policy Rev. 2017 Apr;36(2):181-201
pubmed: 28366968
Fertil Steril. 2021 Jul;116(1):54-63
pubmed: 34148590
Am J Epidemiol. 1998 Jan 15;147(2):95-9; discussion 100-2
pubmed: 9456997
Top Spinal Cord Inj Rehabil. 2018 Spring;24(2):110-120
pubmed: 29706755
Fertil Steril. 2018 Oct;110(5):824-825
pubmed: 30316418

Auteurs

Ann Korkidakis (A)

Boston IVF-The Eugin Group, Waltham, Massachusetts; Department of Obstetrics and Gynecology, Beth Israel Deaconess Medical Center, Boston, Massachusetts; Department of Obstetrics, Gynecology, and Reproductive Biology, Harvard Medical School, Boston, Massachusetts. Electronic address: Akorkidakis@bostonivf.com.

Carol DeSantis (C)

Division of Reproductive Health, Centers for Disease Control and Prevention, Atlanta, Georgia; Department of Obstetrics and Gynecology, University of Connecticut, Farmington, Connecticut.

Dmitry Kissin (D)

Division of Reproductive Health, Centers for Disease Control and Prevention, Atlanta, Georgia.

Michele Hacker (M)

Department of Obstetrics and Gynecology, Beth Israel Deaconess Medical Center, Boston, Massachusetts; Department of Obstetrics, Gynecology, and Reproductive Biology, Harvard Medical School, Boston, Massachusetts.

Katherine Koniares (K)

Department of Obstetrics and Gynecology, University of Connecticut, Farmington, Connecticut.

Anthony Yartel (A)

Division of Reproductive Health, Centers for Disease Control and Prevention, Atlanta, Georgia; Department of Obstetrics and Gynecology, University of Connecticut, Farmington, Connecticut.

Eli Adashi (E)

Department of Medical Sciences, Division of Biology and Medicine, Brown University, Providence, Rhode Island.

Alan Penzias (A)

Boston IVF-The Eugin Group, Waltham, Massachusetts; Department of Obstetrics and Gynecology, Beth Israel Deaconess Medical Center, Boston, Massachusetts; Department of Obstetrics, Gynecology, and Reproductive Biology, Harvard Medical School, Boston, Massachusetts.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH